Evolutionary origin of extrapyramidal disorders in drug-treated mental patients, its significance, and the role of neuromelanin.
D000663:Amphibians; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000473:pathology; D005075:Biological Evolution; D002746:Chlorpromazine / Q000009:adverse effects; D004347:Drug Interactions; D005123:Eye / Q000503:physiopathology; D005399:Fishes; D005917:Globus Pallidus / Q000503:physiopathology; D006801:Humans; D008124:Locomotion; D008297:Male; D008322:Mammals; D008543:Melanins / Q000037:antagonists & inhibitors / Q000502:physiology*; D001523:Mental Disorders / Q000188:drug therapy*; D009055:Mouth / Q000187:drug effects; D009069:Movement Disorders / Q000139:chemically induced; D009132:Muscles / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D012148:Restless Legs Syndrome / Q000139:chemically induced; D013035:Spasm / Q000139:chemically induced; D013045:Species Specificity
D014150:Antipsychotic Agents; D008543:Melanins; D002746:Chlorpromazine